Vedanta Biosciences to Present at Upcoming Investor Conferences

Rhea-AI Summary

Vedanta Biosciences, a pioneering clinical-stage microbiome company, announced participation in several virtual investor conferences. Key events include the Chardan 3rd Annual Microbiome Medicines Summit on March 8, 2021, at 2:00 PM ET; the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 AM ET; and the Credit Suisse 2021 Healthcare Innovators Series on March 11, 2021, at 12:20 PM ET. The company focuses on developing oral therapies for immune-mediated diseases using rationally defined bacterial consortia.

Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using rationally defined bacterial consortia manufactured from clonal cell banks, today announced that members of its executive team will present and host one-on-one meetings at the following virtual investor conferences:

Chardan 3rd Annual Microbiome Medicines Summit
Date: Monday, March 8, 2021
Presentation Time: 2:00 PM ET

H.C. Wainwright Global Life Sciences Conference
Date: Tuesday, March 9, 2021
Presentation Time: 7:00 AM ET

Credit Suisse 2021 Healthcare Innovators Series: Life Sciences Private Company Event
Date: Thursday, March 11, 2021
Presentation Time: 12:20 PM ET

About Vedanta Biosciences

Vedanta Biosciences is leading the development of a potential new category of oral therapies for immune-mediated diseases using rationally defined bacterial consortia manufactured from clonal cell banks. The Company’s approach bypasses the need to rely on direct sourcing of donor fecal material of inconsistent composition, thus overcoming challenges related to safety, quality, and scalability that limit donor-derived approaches. The clinical pipeline includes product candidates being evaluated for the treatment of C. difficile infection, inflammatory bowel diseases, advanced or metastatic cancers, and food allergy. These investigational therapies are grounded in pioneering research – published in leading journals including Science, Nature, and Cell – that identified bacteria that induce a range of beneficial immune responses. The Company’s platform includes what is believed to be the largest library of bacteria derived from the human microbiome, high throughput methods for bacterial consortium design, vast datasets from human interventional studies, and state-of-the-art capabilities for cGMP-compliant manufacturing of defined bacterial consortia. Vedanta Biosciences controls a foundational intellectual property portfolio covering compositions of matter and methods of use for classes of bacteria that play key roles in human health. Vedanta Biosciences was founded by PureTech Health (Nasdaq: PRTC, LSE: PRTC) and a global team of scientific co-founders who pioneered the modern understanding of how the immune system and the microbiome cross-talk.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005408/en/

FAQ

What will Vedanta Biosciences present at the Chardan Microbiome Medicines Summit 2021?

Vedanta Biosciences will present at the Chardan 3rd Annual Microbiome Medicines Summit on March 8, 2021, at 2:00 PM ET.

When is Vedanta Biosciences participating in the H.C. Wainwright Global Life Sciences Conference?

Vedanta Biosciences will participate in the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 AM ET.

What is the date and time for Vedanta Biosciences at the Credit Suisse Healthcare Innovators Series?

Vedanta Biosciences will present at the Credit Suisse 2021 Healthcare Innovators Series on March 11, 2021, at 12:20 PM ET.

What innovative therapies is Vedanta Biosciences developing?

Vedanta Biosciences is developing oral therapies for immune-mediated diseases, including treatments for C. difficile infection and inflammatory bowel diseases.

Who founded Vedanta Biosciences?

Vedanta Biosciences was founded by PureTech Health and a team of scientific co-founders.